• 1 polyethylene single-dose container (s) of 15 ml
• 5 single-dose container (s) of 15 ml
• 10 single-dose container (s) of 15 ml
• 25 single-dose container (s) of 15 ml
• 240 polyethylene single-dose container (s) of 15 ml

• Ready-to-use, single-use solution.
• DO NOT SWALLOW. EXTERNAL USE. DERMAL.
• This product can be applied directly to wounds.
• Do not rinse.

• Hypersensitivity to one of the components (or group sensitization),
• In contact with the brain, the meninges, the eye, the mucous membranes, nor penetrate the ear canal in the event of eardrum perforation.

• Dermal.

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiration date refers to the last day of that month.
• This medication should be stored at a temperature below 30 ° C.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• allergic eczema on contact with the product,
• rarely, general allergic accident up to anaphylactic shock.
• Due to the presence of 90 percent ethanol (alcohol), frequent applications to the skin can cause irritation and dryness of the skin.
• If you notice any side effects not listed in this leaflet, or if any side effects get serious, please tell your doctor or pharmacist.
• Keep out of the reach and sight of children.

• This medication should not be used at the same time as other local antiseptics (risk of incompatibility or ineffectiveness). Prior use of soap should be followed by thorough rinsing.
• If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Although the transcutaneous absorption of chlorhexidine is very low, the risk of systemic effects cannot be excluded. They are all the more to be feared as the antiseptic is used over a large area, on damaged skin (in particular burnt) a mucous membrane, premature or infant skin (due to the surface / weight ratio and the diaper occlusion effect at the seat).
• As soon as the packaging of an antiseptic preparation is opened, microbial contamination is possible.
• The use of chlorhexidine solutions, alcoholic or aqueous, for antisepsis of the skin, before invasive surgery has been associated with chemical burns in newborns. Based on reported cases and published literature, this risk appears to be higher in premature infants, especially those born before 32 weeks of gestation and in the first 2 weeks of life.
• Remove all soaked materials, gowns or drape before proceeding. Do not use excessive amounts and do not leave the solution in folds of the skin or on the patient or on sheets or other material in direct contact with the patient. When occlusive dressings are used on areas previously exposed to HIBIDIL, every precaution should be taken to ensure that there is no excess product prior to application of the dressing.

• As soon as the packaging of an antiseptic preparation is opened, microbial contamination is possible.
• Do not use chlorine-based products (bleach, etc.) to clean fabrics or containers that have been in contact with HIBIDIL: risk of indelible stains.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Solution for local application.
• 15 ml in single-dose container (polyethylene).

• HIBIDIL, solution for local application, sterile, box of 240 single-dose containers of 15 ml
• HIBIDIL, solution for local application, sterile, box of 1 single-dose container of 15 ml

• Azorubine

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Oral infection
• Postoperative care in stomatology

• 1 polyterephthalate (PET) bottle (s) with 5000 ml dosing pump
• 1 polyterephthalate (PET) bottle (s) of 50 ml
• 1 polyterephthalate (PET) bottle (s) of 100 ml
• 1 polyterephthalate (PET) bottle (s) of 300 ml with polypropylene measuring cup
• 1 polyterephthalate (PET) bottle (s) of 500 ml

• For each mouthwash, use the contents of half a scoop (12 ml); if this presentation does not contain a cup, use a tablespoon, i.e. approximately 15 ml.
• Rinse your mouth thoroughly for about a minute with the pure solution.

• allergy to chlorhexidine or to any part of the solution.

• Use locally in mouthwashes.
• DO NOT SWALLOW.
• This solution should be used pure, undiluted.
• Mouthwashes should be done AFTER brushing and rinsing.

• Do not continue treatment for more than 5 days without medical advice.

• Keep out of the reach and sight of children.

• Do not use PAROEX 0.12 PERCENT, solution for mouthwash after the expiry date stated on the outer packaging.

• After opening the bottle, this medication can be stored for a maximum of 30 days (90 days for the 5000 ml format with pump).

• Medicines should not be thrown away with wastewater or household waste. Ask your pharmacist what to do with any unused medicine. These measures will help protect the environment.

• Brown discoloration of the tongue and teeth, particularly in tea and coffee users, disappearing when treatment is stopped.
• Possibility of allergic reactions: irritations, skin reactions, swelling of the salivary glands, swelling of the neck or face. If you experience any of these symptoms, stop treatment and see a doctor.
• Possibility of taste alteration or burning sensation of the tongue at the start of treatment.
• Occasionally, peeling of the oral mucosa.

• Do not use several medicines containing an antiseptic at the same time or in close proximity.
• IN ORDER TO AVOID POSSIBLE INTERACTIONS BETWEEN SEVERAL MEDICINES, ANY OTHER TREATMENT IN PROGRESS MUST BE SENIORIZED TO YOUR DOCTOR OR YOUR PHARMACIST.

• DO NOT LEAVE THIS MEDICINE WITHIN THE REACH OF CHILDREN.
• Prolonged use of this medication is undesirable because it can alter the natural microbial balance in the mouth and throat.

• Do not put the product in contact with the eyes.
• Do not introduce the product into the nose or ears.
• KEEP OUT OF REACH OF CHILDREN.
• DO NOT SWALLOW.
• IF IN DOUBT, DO NOT HESITATE TO ASK FOR THE OPINION OF YOUR DOCTOR OR YOUR PHARMACIST.

• This drug should be used with caution during pregnancy and lactation.
• In general, you should seek advice from your doctor or pharmacist before taking any medication.

• Not applicable.

• Not applicable.

• Not applicable.

• PAROEX 0.12 PERCENT, solution for mouthwash, 100 ml vial
• PAROEX 0.12 PERCENT, mouthwash solution, 5000 ml vial
• PAROEX 0.12 PERCENT, solution for mouthwash, 50 ml vial
• PAROEX 0.12 PERCENT, solution for mouthwash, 300 ml bottle

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Medicinal product withdrawn from the market on 07/03/2006

• Non-infectious conjunctival irritation

• Local route.
• RESERVED FOR ADULTS AND CHILDREN OVER 12 YEARS OLD. IN EYE INSTILLATION.
• One drop of eye drops 2 to 4 times a day.
• Instill 1 drop of eye drops in the lower conjunctival cul-de-sac of the diseased eye (s) by looking upwards and pulling the lower eyelid slightly downwards.
• Do not touch the eye or the eyelids with the tip of the bottle. Recap the bottle after use.

•  hypersensitivity to one of the constituents of the eye drops,
• risk of glaucoma by closing the angle.

• pregnancy: there are no reliable data on teratogenesis in animals.
• There is currently no relevant, or sufficient number, to assess a possible malformative effect of synephrine when administered during pregnancy.
• Consequently, the use of drugs containing synephrine is not recommended during the first trimester.
• Breast-feeding: due to the lack of data on the passage of this drug in breast milk, the use of this one should be avoided during breast-

• feeding.
• in combination with bromocriptine; guanethidine and related; non-selective MAOIs (iproniazid, nialamide) (see interactions).

• Risk of acute glaucoma by closing the angle.
• Possibility of transient irritation.
• Possibility of allergic reactions: blepharitis, conjunctivitis.
• Repeated instillations can cause an annoying mydriasis, superficial punctate keratitis; exceptionally, by systemic effect of synephrine, an increase in blood pressure, tremors, pallor, headaches, cardiac arrhythmias.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Oral infection
• Postoperative care in stomatology

• 1 polyterephthalate (PET) bottle (s) of 55 ml
• 1 polyterephthalate (PET) bottle (s) of 200 ml with measuring cup (s)
• 1 polyterephthalate (PET) bottle (s) of 500 ml

• RESERVED FOR ADULTS AND CHILDREN OVER 6 YEARS OLD.
• 200 ml bottle: For each mouthwash, use the measuring cup, filling it up to the mark (15 ml). If there is no cup, use the contents of one tablespoon of solution (15 ml).
• 55 ml and 500 ml bottles: Use the content of one tablespoon of solution (i.e. 15 ml).
• Rinse mouth thoroughly for about a minute with the pure solution.

• The number of mouthwashes is 1 to 3 per day.

• allergy to chlorhexidine.

• Use locally as a mouthwash.
• DO NOT SWALLOW.
• This solution should be used pure, undiluted.
• Mouthwashes should be done AFTER brushing and rinsing.

• Pharmacotherapeutic group: STOMATOLOGY / LOCAL ANTISEPTIC TREATMENT, ATC code: A01AB03.

• Keep this medication out of the sight and reach of children.
• Do not use PREXIDINE 0.12 PERCENT, solution for mouthwash after the expiry date stated on the outer packaging. The expiration date refers to the last day of the month.
• Store at a temperature not exceeding + 25 ° C.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Brown discoloration of the tongue and teeth, especially in tea or coffee drinkers, disappearing when treatment is stopped.
• Possibility of allergic reactions: irritations, skin reactions, swelling of the salivary glands. If you experience any of these symptoms, stop treatment and see a doctor.
• Possibility of taste alteration or burning sensation of the tongue at the start of treatment.

• Do not use several medicines containing an antiseptic at the same time or in close proximity.
• IN ORDER TO AVOID POSSIBLE INTERACTIONS BETWEEN SEVERAL MEDICINES, ANY OTHER TREATMENT IN PROGRESS MUST BE SIGNIFICANTLY TO YOUR DENTAL SURGEON, YOUR STOMATOLOGIST OR YOUR PHARMACIST.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• The indication does not justify prolonged treatment, especially since it could expose to an imbalance of the normal microbial flora of the oral cavity, with a risk of bacterial or fungal diffusion (candidiasis).
• In the event of persistence of symptoms beyond 5 days and / or associated fever, the action to be taken should be reassessed and systemic antibiotic therapy should be considered.
• Interrupt the treatment in case of swelling of the parotids.

• Do not put the product in contact with the eyes or nose.
• Do not introduce the product into the ear canal.
• Due to the presence of alcohol:
• Keep out of the reach of children.
• Do not swallow.

• This drug should be used with caution during pregnancy and lactation.
• In general, you should seek advice from your doctor or pharmacist before taking any medication.

• An overdose is not expected under normal conditions of use of this mouthwash solution.
• In the event of accidental oral ingestion of chlorhexidine, the following effects have been reported: atrophic gastritis, esophageal and hepatic lesions in case of very high doses.
• In the event of accidental ingestion in children, take into account the presence of alcohol (0.1 g / ml).
• In addition, this specialty contains terpene derivatives, as excipients, which can lower the epileptogenic threshold and cause, in excessive doses, in the event of accidental oral ingestion, neurological accidents in children (such as convulsions). and in the elderly (agitation and confusion type). Follow the recommended mode and route of administration, dosages and duration of treatment (see section Posology and method of administration).
• An accidental projection by the ocular route of a solution of chlorhexidine is likely to cause corneal lesions requiring specialized care.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• PREXIDINE 0.12 PERCENT, solution for mouthwash, bottle (+ measuring cup) of 200 ml
• PREXIDINE 0.12 PERCENT, solution for mouthwash, 500 ml bottle
• PREXIDINE 0.12 PERCENT, solution for mouthwash, 300 ml bottle

• Excipients (common): saccharin, glycerol, polysorbate 80, alcohol, levomenthol, mint flavor (ethanol, menthol, menthyl acetate, mint essential oil), purified water.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Medicinal product withdrawn from the market on 09/11/2014

• Affection limited to the oral mucosa and oropharynx

• Local antibacterial and analgesic adjunctive treatment of affections limited to the oral mucosa and the oropharynx.
• NB: given the general clinical signs of bacterial infection, general antibiotic therapy should be considered.

• 1 spray 4 to 6 times a day.
• Avoid breathing in while spraying.

• Known allergy to local anesthetics and hexetidine.
• Do not use in children under 15 years old.

• This medicine contains 0.22 g of alcohol per spray. It is not recommended in patients suffering from liver disease, alcoholism, epilepsy, as well as in pregnant women.
• Pregnancy: in the absence of experimental and clinical data with this combination, ANGISPRAY is not recommended during pregnancy.
• Breast-feeding: in the absence of data on the passage of this medication into breast milk, ANGISPRAY should be avoided during breast-feeding.

• Anaphylactic reaction
• Numbness of the tongue
• Wrong way
• Irritation of the oral mucosa
• Dryness of the oral mucosa

• The simultaneous or successive use of other antiseptics should be avoided given the possible interferences (antagonism, inactivation).
• Hexetidine is inactivated by alkaline solutions.
• Hexetidine is inactivated by alkaline solutions.

• Possibility of aspiration by anesthesia of the oropharyngeal crossroads:
• do not use this medication before meals or before taking a drink.
• The indication does not justify a prolonged treatment beyond 5 days, especially since it could expose to an imbalance of the normal microbial flora of the oral cavity with a risk of bacterial or fungal diffusion.
• Repeated or prolonged treatment in the mucosa may expose the risks of toxic systemic effects of contact anesthetics (damage to the central nervous system with convulsions, depression of the cardiovascular system).

•  In the event of persistence of symptoms beyond 5 days and / or associated fever, the action to be taken must be reassessed.
• This medicine contains approximately 0.22 g of alcohol per spray. It is not recommended in patients suffering from liver disease, alcoholism, epilepsy, as well as in pregnant women.

• In the absence of experimental and clinical data with this combination, ANGI SPRAY is not recommended during pregnancy.

• In the absence of data on the passage of this medication into breast milk, ANGI SPRAY should be avoided during breast-feeding.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Lack of information in the MA.
• 40 ml pressurized bottle (glass).

• is not present in the composition of this drug

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Medicinal product withdrawn from the market on 03/30/2015

• Vitamin-calcium deficiency in the elderly
• Osteoporosis

• in the elderly, in the event of calcium and vitamin D deficiencies,
• in combination with treatments for osteoporosis, when the intake of calcium and vitamin D is insufficient.

• history of allergy to vitamin D or to one of the constituents,
• prolonged immobilization,
• abnormally high amount of calcium in the blood (hypercalcaemia),
• exaggerated elimination of calcium through the urine (hypercalciuria),
• kidney stones (calcium lithiasis),
• phenylketonuria (hereditary disease due to enzyme deficiency), due to the presence of aspartame.

• Oral route

• Comply with your doctor’s prescription.

• Vitamin D corrects the insufficient intake of vitamin D.
• It increases the intestinal absorption of calcium and its fixation on the osteoid tissue.
• Calcium intake corrects dietary calcium deficiency.
• The daily calcium requirements are of the order of 1000 to 1500 mg of elemental calcium and 500-1000 IU / day of vitamin D.
• Vitamin D and calcium correct secondary senile hyperparathyroidism.
• An 18-month, double-blind, placebo-controlled study involving 3270 women aged 84 + – 6 years living in health centers, showed a significant decrease in plasma PTH levels. At 18 months, the results of the intention-to-treat analysis revealed 80 hip fractures in the calcium-vitamin D group and 110 hip fractures in the placebo group (p = 0.004). Under the conditions of this study, the treatment of 1387 women prevented 30 hip fractures. After an extension up to 36 months, the following results were obtained: 137 hip fractures in the calcium-vitamin D group and 178 in the placebo group (p <= 0.02).

• constipation or diarrhea,
• bloating, stomach pain,
• nausea,
• too great an increase in the level of calcium in the blood or urine, in the event of prolonged treatment,
• itching, extensive rash, hives.

• Decrease in the digestive absorption of cyclins.
• Take calcium salts away from cyclins (more than 2 hours, if possible).

• Risk of rhythm disturbances.
• Clinical monitoring and, if necessary, control of ECG and serum calcium.

• Risk of reduced digestive absorption of bisphosphonates.
• Take calcium salts away from bisphosphonates (more than 2 hours, if possible).

• Decreased digestive absorption of estramustine.
• Take calcium salts away from estramustine (more than 2 hours if possible).

• Decreased digestive absorption of iron salts.
• Take iron between meals and in the absence of calcium.

• Risk of hypercalcemia by reduction of urinary calcium elimination.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• of prolonged treatment, it is necessary to have the quantity of calcium excreted in the urine checked regularly (calciuria). Depending on the result, your doctor may need to reduce or even interrupt your treatment.
• additional administration of calcium and vitamin D in high doses which must be done under strict medical supervision.
• associated treatment with bisphosphonates as well as in case of treatment with an antibiotic of the cyclin family, it is advisable to wait at least two hours between the intakes of these drugs and OSTEOCAL D3, tablet to suck
• sarcoidosis or kidney failure.
• galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency (rare metabolic diseases), due to the presence of lactose.
• fructose intolerance (hereditary metabolic disease), due to the presence of sorbitol.

• vitamin D overdose during gestation has had teratogenic effects in animals.
• in pregnant women, vitamin D overdoses should be avoided because permanent hypercalcemia can cause physical and mental retardation in children, supravalvular aortic stenosis or retinopathy. However, several children were born without malformation after administration of very high doses of vitamin D3 for hypoparathyroidism in the mother.
• vitamin D and its metabolites pass into breast milk.

• Tell your doctor or pharmacist immediately.
• Taking an excessive dose of this medication may cause the following symptoms: nausea, vomiting, intense thirst, constipation.
• In case of prolonged overdose, calcifications may appear in the vessels or tissues.

• Do not take a double dose to make up for the dose you forgot to take.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• White round tablet.
• 60 tablets in a bottle (PE).

• This medication is in the form of a tablet to suck. Box of 60.

• Aspartame, Lactose monohydrate, Sorbitol

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• in the treatment of calcium and vitamin D deficiencies in the elderly,
• in combination with treatment for osteoporosis when calcium and vitamin D intake is insufficient.

• 1 polyethylene bottle (s) of 30 tablet (s)
• 1 polyethylene bottle (s) of 60 tablet (s)
• 1 polyethylene bottle (s) of 90 tablet (s)
• 1 polyethylene bottle (s) of 180 tablet (s)

• If you are allergic to vitamin D or any of the other ingredients of Caltrate Vitamin D3.
• if you have an abnormally high amount of calcium in your blood (hypercalcaemia) and / or excessive exaggeration of calcium in the urine (hypercalciuria)
• if you have kidney stones (calcium lithiasis)
• if you have too much vitamin D (hypervitaminosis D)

• Caltrate Vitamin D3 is presented as film-coated tablets for oral use.
• The usual dose is 2 tablets per day, to be swallowed with a full glass of water.

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date, which is stated on the pack and the bottle after the abbreviation “EXP”. The expiration date refers to the last day of the month indicated.
• This medication should be stored at a temperature not exceeding 25 ° C. Keep the bottle tightly closed, in a dry place.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Uncommon side effects (affects 1 to 10 users in 1,000): excessive calcium levels in the blood or urine.
• Rare side effects (affects 1 to 10 users in 10,000): constipation, bloating, nausea, abdominal pain, diarrhea, itching, rash and hives.
• Other side effects (frequency not known): kidney stones.
• If you get any of the side effects gets serious, or if you get any side effects not listed in this leaflet, please tell your doctor or pharmacist.
• Keep out of the reach and sight of children.

• Thiazide diuretics reduce urinary calcium excretion. Due to the increased risk of hypercalcaemia, monitoring of serum calcium is recommended with simultaneous administration of thiazide diuretics.
• Systemic corticosteroids reduce the absorption of calcium. In case of concomitant administration of corticosteroids, it may be necessary to increase the dose of Caltrate Vitamin D3.
• Combination therapy with ion exchange resins like cholestyramine or laxatives like paraffin oil may reduce gastrointestinal absorption of vitamin D3.
• Calcium carbonate may affect the absorption of tetracyclines when administered simultaneously. It is recommended to postpone the intake of tetracyclines at least 2 hours before or 4 to 6 hours after oral intake of calcium.
• Hypercalcemia can increase the toxicity of digitalis when calcium and vitamin D are administered simultaneously. Patients should therefore be monitored regularly (ECG control and calcium levels).
• In case of concomitant administration of a bisphosphonate or sodium fluoride, it is recommended to postpone the intake of Caltrate Vitamin D3 by at least 3 hours, their digestive absorption may be reduced.
• Oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole grains) can inhibit calcium absorption by forming insoluble compounds with calcium ions. The patient should not take any products containing calcium within two hours of eating foods rich in oxalic acid and phytic acid.

• In the event of prolonged treatment with Caltrate Vitamin D3, it is necessary to have the amount of calcium present in the blood checked regularly (calcemia). This control is particularly important in the elderly and during associated treatment based on cardiac glycosides or diuretics. Depending on the result, your doctor may need to reduce or even interrupt your treatment.
• If you frequently have kidney stones.
• If your doctor has told you that you have kidney failure.
• If your doctor has told you that you have sarcoidosis
• If you are immobilized and you have reduced bone mass (osteoporosis)
• If you are taking other medicines containing vitamin D3 or calcium

• During pregnancy, the daily dose should not exceed 1500 mg of calcium and 600 IU of vitamin D. Studies in animals have shown reproductive toxicity at high doses of vitamin D. In pregnant women, any overdose of calcium and vitamin D should be avoided because permanent hypercalcemia has been associated with negative effects on fetal development. There is no evidence that vitamin D3 at a therapeutic dose is teratogenic in humans.
• Caltrate Vitamin D3 can be administered during pregnancy, in case of calcium and vitamin D3 deficiency.

• Caltrate Vitamin D3 can be administered during breast-feeding. Calcium and vitamin D3 pass into breast milk. This should be taken into account in the case of concomitant administration of vitamin D3 in children.

• If you have further questions on the use of this medicine, ask your doctor or pharmacist for more information.

• Not applicable.
• Not applicable.
• Not applicable.

• Calcium carbonate: 1498.50 mg
• Quantity corresponding to elemental calcium: 600.00 mg
• Cholecalciferol or vitamin D3: 400.00 IU
• For a scored film-coated tablet.

• Microcrystalline cellulose, povidone, crospovidone, sodium laurilsulfate, croscarmellose sodium, magnesium stearate, OPADRY OY-S-27203, light liquid paraffin, talc.

• Gray / beige, oblong film-coated tablet. One of the faces bears a score bar with “D” engraved on the left of the bar, and “600” on the right side. “Caltrate” is printed on the other side.
• Bottles of 20, 30, 60, 90 and 180 tablets. Not all presentations may be marketed.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Vitamin D deficiency

• insufficient exposure to the sun,
• a diet low in vitamin D.

• Without milk enriched with vitamin D or in children with pigmented skin: 1 vial every 6 months.

• Without digestive pathology: 1 ampoule at the beginning of winter
• With digestive pathology or receiving anti-convulsants: 1 ampoule every 3 months.

• 1 ampoule, renewable once for 6 months, then resume the usual prophylaxis to prevent relapses. Do not exceed a total dose of 600,000 IU / year.

• Elderly subject: 1 ampoule every 6 months.
• Adult at risk of deficiency (digestive pathology, in an institution, anti-convulsant treatment, etc.): 1 ampoule every 6 months.

• 1 ampoule renewable once or twice over 6 months, then resume the usual prophylaxis to prevent relapses. Do not exceed a total dose of 600,000 IU / year.

• known allergy to vitamin D or any of the other constituents;
• hypercalcemia (excess calcium in the blood), hypercalciuria (excess calcium in the urine), calcium lithiasis (kidney stones).

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiration date refers to the last day of that month.
• Store at a temperature not exceeding 25 ° C.
• Keep the ampoule in the outer carton in order to protect from light.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Skin and subcutaneous tissue disorders: pruritus, rash, erythema, edema.

• Decrease in vitamin D concentrations more marked than without treatment with inducers.
• Determination of vitamin D concentrations and supplementation if necessary.

• Decrease in vitamin D concentrations more marked than without treatment with rifampicin.
• Determination of vitamin D concentrations and supplementation if necessary.

• Decreased absorption of vitamin D.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• If needed, vitamin D can be prescribed during pregnancy. ZYMAD 200,000 IU is not a suitable strength for pregnant women.
• Ask your doctor or pharmacist for advice before taking any medicine.

• If needed, vitamin D can be prescribed during breastfeeding. However, this supplementation does not replace the administration of vitamin D in the newborn.
• Ask your doctor or pharmacist for advice before taking any medicine.

• · Headache, fatigue, loss of appetite, weight loss, stunted growth;
• · Nausea, vomiting;
• Profuse urine, intense thirst, dehydration;
• · Kidney stones, calcification of tissues, especially kidney and vessels;
• · Renal failure (failure of kidney function).

• · Increase in calcium levels in the blood and urine and increased phosphorus levels in the blood and urine, low concentration and high parathyroid hormone 25-hydroxyvitamin D .
• In the event of an overdose, treatment should be stopped, calcium intake (dairy) limited and your doctor should be consulted.

• N o not take a double dose to make up the dose you missed.

• Not applicable.
• Not applicable.
• Not applicable.

• Oral solution in ampoule.
• 2 ml in 5 ml ampoule (type III brown glass) with breakable tip. Box of 1.

• ZYMAD 50,000 IU Oral solution box of 1 ampoule of 2 ml
• ZYMAD 80,000 IU Oral solution box of 1 ampoule of 2 ml
• ZYMAD 10,000 IU / ml, oral solution in drops, box of 1 vial (+ dropper) of 10 ml.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Medicinal product withdrawn from the market on 15/10/2015

• Oral cavity infection
• Postoperative care in stomatology

• 1 125 ml amber glass vial (s)
• 1 125 ml amber glass bottle (s) with polypropylene measuring cup
• 1 500 ml amber glass vial (s)

• Local use in mouthwash.
• Do not swallow.
• 2 to 4 mouthwashes per day, by pouring 10 ml of this product into the measuring cup and completing with water up to the 50 ml mark.

• Known allergy to hexetidine, chlorobutanol, salicylates or a drug of similar activity (NSAIDs, aspirin).
• IN CASE OF DOUBT, IT IS ESSENTIAL TO ASK YOUR OPINION OF YOUR DENTIST OR OSTOMATOLOGIST AND / OR YOUR DOCTOR OR PHARMACIST .

• Use locally as a mouthwash.
• Do not swallow.

• The treatment should not exceed 5 days without medical advice.

• Keep out of the reach and sight of children.

• Do not use GIVALEX, solution for mouthwash after the expiry date stated on the outer packaging.
• Storage conditions
• Store away from light.

• Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist what to do with any unused medicine. These measures will help protect the environment.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• DO NOT LEAVE THIS MEDICINE WITHIN THE REACH OF CHILDREN.
• Prolonged use (more than 5 days) of this medication is undesirable because it can modify the natural microbial balance of the mouth, throat.

• If symptoms worsen or no improvement after 5 days: CONSULT YOUR DOCTOR.
• IN CASE OF DOUBT, DO NOT HESITATE TO ASK FOR THE ADVICE OF YOUR DOCTOR OR PHARMACIST.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Lack of information in the MA.
• 125 ml type III amber glass bottle with measuring cup (polypropylene), closed with a cap fitted with a low density polyethylene seal.

• GIVALEX, solution for mouthwash, 125 ml bottle
• GIVALEX, mouthwash, 50 ml spray bottle

• is not present in the composition of this drug

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Inflammatory condition of the oral mucosa
• Ulcerative condition of the oral mucosa

• 1 polypropylene tube (s) of 3 g
• 1 polypropylene tube (s) of 5 g
• 1 polypropylene tube (s) of 12 g
• 1 polypropylene tube (s) of 15 g
• 1 polypropylene tube (s) of 30 g
• 1 polyethylene tube (s) of 3 g
• 1 polyethylene tube (s) of 15 g
• 1 polyethylene tube (s) of 30 g

• This medicine is only for adults.

• Clean and dry prosthetic devices before application.
• On average, 1 to 4 applications (the value of a dab of gel) per day.
• In the case of permanent prostheses: deposit the value of a pea of ​​gel on the incisors or molars next to the painful gum.
• In the case of temporary prostheses: place the gel on the part of the device corresponding to the extractions.
• Once in the mouth, the gel spreads evenly under the effect of temperature and chewing.

• history of allergy to salicylate drugs (aspirin.)

• Hypersensitivity reactions to salicylate drugs,
• Risk of irritation due to the presence of alcohol.

• THIS MEDICINE IS ONLY FOR ADULTS.
• If there is no improvement after a few days, see your dental specialist. In fact, irritation due to your prosthesis may require it to be adapted and the application of this treatment only constitutes a waiting gesture.
• WARNING, THIS MEDICINE CONTAINS 39 G OF ALCOHOL PER 100 g.

• IF IN DOUBT, IT IS ESSENTIAL TO ASK YOUR DENTAL SPECIALIST FOR THE ADVICE.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Oral gel.
• Tube (polyethylene) closed with a 15 g polypropylene stopper.

• This medication is in the form of an oral gel. Box of 1 tube of 3, 5, 12, 15 or 30 g.
• Not all presentations may be marketed.

• is not present in the composition of this drug

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Drug withdrawn from the market on 08/24/2018

• Contact eczema
• Atopic dermatitis
• Stasis dermatitis
• Psoriasis
• Seborrheic dermatitis except the face
• Insect bite
• Parasitic prurigo

• allergy to any component of the drug
• ulcerated lesions
• acne
• rosacea
• infectious diseases of the skin of viral (herpes, shingles, chickenpox, etc.), bacterial (example: impetigo, etc.), mycotic (due to microscopic fungi) or parasitic origin.
• application on the eyelids

• It is advisable to apply the product in spaced strokes, then to spread it by massaging lightly until it is fully absorbed.
• Wash hands after application.

• 1 to 2 applications per day as prescribed by your doctor

• The treatment will be stopped gradually, by spacing out the applications and / or by using a less strong or less dosed corticosteroid.
• Strictly follow your doctor’s prescription and do not prolong the treatment.

• Topical corticosteroids are classified into 4 activity levels according to skin vasoconstriction tests: very strong, strong, moderate, weak activity.
• Locacortene Vioforme contains a corticosteroid of moderate activity and an antiseptic, clioquinol.
• Flumetasone pivalate is the essential active substance.
• Active on certain inflammatory processes (for example: contact hypersensitivity) and the pruritic effect which is linked to them. Vasoconstrictor. Inhibits cell multiplication.

• Keep out of the reach and sight of children.

• Do not use ALKOCORTENBIOFORM, cream after the expiry date stated on the outer packaging.

• Store at a temperature below 25 ° C.

• Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist what to do with any unused medicine. These measures will help to protect the environment.

• With prolonged use, there is a risk of thinning and fragility of the skin, dilation of small blood vessels, stretch marks, acne breakout.
• Cases of exaggerated development of the hair system, discoloration of the skin, secondary infection in particular in the event of treatment under an occlusive dressing or in the folds, have been reported.

• Yellowish discoloration of the skin disappearing quickly.
• If you notice any side effects not listed in this leaflet, or if any side effects get serious, please tell your doctor or pharmacist.
• Keep out of the reach and sight of children.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• The prolonged use on the face of corticosteroids with moderate activity exposes to the occurrence of corticosteroid-induced and paradoxically corticosensitive dermatitis, with rebound after each stop. A gradual weaning, particularly difficult, is then necessary.
• Due to the passage of the corticosteroid into the systemic circulation, treatment over large areas or under occlusion may cause the systemic effects of systemic corticosteroid therapy, particularly in infants and toddlers. They consist of a cushingoid syndrome and a slowing of growth. These accidents disappear when treatment is stopped, but abrupt cessation can be followed by acute adrenal insufficiency.

• In infants, it is preferable to avoid corticosteroids of moderate activity. One should be particularly wary of spontaneous occlusion phenomena which may occur in the folds or under the layers.
• In the event of a bacterial or mycotic infection of a corticosensitive dermatosis, precede the use of the corticosteroid with a specific treatment.
• If a local intolerance appears, the treatment must be interrupted and the cause must be sought.
• Breast-feeding: during oral treatment, breast-feeding should be avoided because corticosteroids are excreted in breast milk. By local route, the transdermal passage and therefore the risk of excretion of the corticosteroid in the milk will depend on the surface treated, the degree of epidermal damage and the duration of treatment.

• No teratogenicity studies have been performed with topical corticosteroids.
• However, studies concerning the intake of oral corticosteroids have not revealed a higher risk of malformation than that observed in the general population.

• During oral treatment, breast-feeding should be avoided because corticosteroids are excreted in breast milk.

• Always use ALKOCORTENBIOFORM, cream as your doctor has told you.
• Excessive or prolonged use of topical corticosteroids may be the cause of exacerbation of undesirable effects, and systemic passage is not excluded.
• In case of systemic overdose, appropriate symptomatic treatment is indicated. If you have used more ALKOCORTENBIOFORM, cream than you need, contact your doctor.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Lack of information in the MA.
• 15 g sealed aluminum tube coated internally with epoxyphenolic varnish and closed with a high density polyethylene stopper.

• Cetyl alcohol, Stearyl alcohol

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• 1 st week: 1 tablet daily, during dinner;
• 2nd week: 2 tablets daily, 1 during lunch, 1 during dinner;
• From the 3 rd week: 3 tablets per day, 1 breakfast, 1 lunch, 1 dinner.

• Facilitating the penetration and cellular use of glucose (rat);
• Decreased hyperglycemia in the diabetic rat (insulin proprio or not), decreased hyperglycemia (measured by HPO area) in the rabbit.

• A decrease in serum uric acid level of approximately 14% was observed in patients with hyperuricemic obesity treated with Pediatric in combination with a suitable diet.

• Digestive disorders (nausea, vomiting, gastralgia, diarrhea), asthenia, drowsiness or dizziness. However, they are observed more particularly at dosages greater than 3 tablets per day and vary according to the individual susceptibilities;
• Very rare cases of anaphylactic reactions, hypotension, shock, skin rash, urticaria, Quicke’s edema;

• The metabolic disorders associated with a treatment with Picks are mainly observed in adults. Prescription Mediator is not justified in children.
• If, after a period of administration of a few months (3 to 6 months), a satisfactory decrease in serum glucose concentrations is not obtained, additional or different therapeutic means should be considered.
• The attention of athletes will be drawn to the fact that this specialty contains an active ingredient that can induce a positive reaction tests conducted during doping controls.
• Due to the presence of sucrose, this drug should not be used in cases of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency.

• Studies in animals have not shown any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have proved teratogenic in animals in well conducted studies on two species.
• Clinically, there are currently no data of sufficient relevance to evaluate the possible malformative or foetotoxic effect of benfluorex when administered during pregnancy.
• Therefore, as a precaution, it is best not to use this medicine during pregnancy. In case of accidental exposure, this treatment should be discontinued.

• In the absence of data on the passage of benfluorex in breast milk, this drug is not recommended during breastfeeding

• White coated domed stick tablet.

• MEDIATOR 150 mg, coated tablet, box of 30

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Corticosteroid-sensitive dermatoses (skin diseases) with a keratotic component (with thickening of the skin or scaly skin.
• Dermatoses located more particularly on the scalp, in the hairy regions and the folds.

• Preferred indications where local corticosteroid therapy is considered the best treatment:
• Lichenification.
• Indications where corticosteroid therapy is one of the usual treatments:
• ·psoriasis,
• ·lichen,
• Seborrheic dermatitis except the face.

• 1 polyethylene bottle (s) of 15 g
• 1 polyethylene bottle (s) of 30 g
• 1 polyethylene bottle (s) of 100 g

• Applications will be limited to 2 per day for one to two weeks; in maintenance treatment, a single daily application may be sufficient. An increase in the number of applications could worsen the side effects without improving the therapeutic effects.
• The treatment of large surfaces requires special monitoring (number of tubes used).
• The treatment will be stopped gradually by spacing out the applications or by using a less strong or less dosed corticosteroid or alternating with a base without a dermocorticoid.

• allergy (hypersensitivity) to the active substance or to any of the ingredients of DIPROSALIC lotion,
• ulcerated lesions,
• acne,
• rosacea (rosacea),
• infectious skin diseases of viral (herpes, shingles, chickenpox), bacterial (example: impetigo, etc.), mycotic (due to microscopic fungi) or parasitic origin,
• in infants,
• DIPROSALIC is not intended for ophthalmic use.

• Dermal.
• It is advisable to apply the medicine in spaced areas, then to spread it with a plastic glove. In scalp conditions, the lotion will be applied line by line, well beyond the surface to be treated. In case of manual use, wash hands after application.

• Usually the treatment will be short. The treatment will be stopped gradually by spacing out the applications and / or by the use of a less strong or less dosed corticosteroid.
• Prolonged use, use on the face or in children should be subject to strict medical supervision.

• Pharmacotherapeutic group: Corticosteroids with strong activity, other combinations, ATC code: D07XC01
• DIPROSALIC is a strong potency dermocorticosteroid (class II) combined with salicylic acid.
• The topical corticosteroid is active on the inflammatory process and the pruritic effect associated with it.
• It has vasoconstrictive (anti-perspirant) properties and inhibits cell multiplication and synthesis processes in the dermis and epidermis.
• Keratolytic action of salicylic acid.

• 36 months.

• 18 months.

• 6 weeks.

• appearance or worsening of rosacea (see “Never use DIPROSALIC, lotion in the following cases”),
• delayed healing of wounds, bedsores (rubbing lesions of the skin), leg ulcers (black scab surrounded by a red inflammatory area),
• possible effects due to the passage of part of the active ingredients in the blood (see “Special warnings”)
• cases of hypertrichosis (abnormal development of the hair system), depigmentation, secondary infections, in particular in the event of treatment under an occlusive dressing or in the folds, have been reported.

• Based on local use of this product: At recommended doses, betamethasone for topical use is not likely to cause medically significant drug interactions.
• If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Do not apply on mucous membranes or in the eyes.
• It is necessary to avoid the applications on large surfaces, under a dressing, under a diaper or in the folds, in particular in the children, because of possible passage of part of the active principles in the blood.

• exact location of applications,
• treatment in children under 12 must be subject to strict medical supervision,
• do not apply to the face, except when prescribed by your doctor.

• avoid prolonged application on the face, in the folds,
• any local irritation or infection should be reported to your doctor,
• if an intolerance reaction appears, the treatment should be stopped,
• if use under occlusion is necessary, it should be monitored due to the risk of superinfection.

• Clinical data from a large number of pregnancies exposed by the systemic route to corticosteroids have not shown an increase in the overall rate of malformations, although studies in animals by the systemic route have shown a teratogenic effect.
• In humans, no particular malformative effects have been reported with salicylic acid. Fetal toxicity reported with NSAIDs is not expected with Diprosalic given the very low systemic concentrations under normal conditions of use.
• The use of Diprosalic during pregnancy can be envisaged in strict compliance with the conditions of use: application to a skin surface <10% of the body surface, treatment duration limited to 4 weeks.
• The mother may experience a prolonged bleeding time as well as the newborn if treated until delivery.

• Corticosteroids and salicylic acid pass into the milk. Due to topical use, Diprosalic can be administered during breast-feeding.
• Do not apply on the breasts.

• Excessive or prolonged use of topical corticosteroids may lead to inhibition of the hypothalamic-pituitary axis resulting in secondary adrenal insufficiency and be the cause of manifestations of hypercorticism, including Cushing’s disease.
• Excessive or prolonged use of topical preparations containing salicylic acid may cause symptoms of salicylic intoxication.

• Appropriate symptomatic treatment is indicated. Symptoms of acute hypercorticism are usually reversible. Correct electrolyte disturbances if necessary.
• In the event of chronic toxicity, a gradual stopping of corticosteroids is advised. Treatment of salicylate poisoning is symptomatic.
• Salicylic acid must be eliminated quickly. Orally administer sodium bicarbonate solution to alkalinize the urine and increase diuresis.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Ointment:   Tube of 30 g.
•  Lotion:   Bottle of 30 g.

• Excipients: thick petrolatum oil, white petrolatum.

• Excipients: hydroxypropylmethylcellulose, sodium hydroxide, sodium edetate, isopropyl alcohol, purified water.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• RESERVED FOR ADULTS AND CHILDREN OVER 6 YEARS OLD.
• Local use in mouthwash.
• DO NOT SWALLOW.
• Four mouthwashes per day, after diluting 1 to 2 teaspoons of the product in a glass of lukewarm water.

• Povidone hypersensitivity
• Pregnancy from the 2nd trimester
• Feeding with milk
• Premature
• Newborn (0 to 1 month)
• Child from 1 month to 6 years old

• Premature and Newborn (under 1 month).
•  In order  extended  for the second and third trimester of pregnancy.
• Breastfeeding is against-indicated in cases of prolonged treatment.

•  In children under 6 years.

1. Povidone iodine is an iodophoric product.
2. It is an organic complex composed of about 10% active iodine available.
3. Its spectrum of activity is that of iodine (antiseptic bactericide on all bacteria and fungicide on yeasts and filamentous fungi).

1. In case of repeated administrations and excessive use, this product may, on the one hand be irritating to the mucous membranes, on the other hand it can occur iodized overload likely to cause thyroid dysfunction.
2. Due to the presence of terpene derivatives and in case of non-compliance with the recommended doses, possibility of agitation and mental confusion in the elderly.

• Mercurial antiseptics : erythema, phlyctenes, and even mucocutaneous necrosis (formation of a caustic complex when concomitant use of iodized and mercurial antiseptics).
• The interaction depends on the stability of the organomercurial at the cutaneous level and the individual sensitivity.

1. If symptoms persist for more than 5 days and / or associated fever, the course of action should be evaluated again.
2. Due to possible absorption of iodine through the mucosa, repeated or prolonged treatment may pose a risk of systemic effects  , particularly thyroid dysfunction.
3. In case of a history of epilepsy, take into account the presence of terpene derivatives (mint flavor).

1. The indication does not justify a prolonged treatment, especially as it could expose to an imbalance of the normal microbial flora of the oral cavity with a risk of bacterial or fungal diffusion.
2. Given the possible interference (antagonism, inactivation), the simultaneous or successive use of antiseptics should be avoided.
3. Possible interference with functional exploration of the thyroid

1. Since the fetal thyroid begins to fix iodine after 14 weeks of amenorrhea, no repercussions on the fetal thyroid are expected in case of prior administrations.
2. Iodine overload, very likely with prolonged use of this product after this term, can lead to fetal hypothyroidism, biological or even clinical (goiter).
3. Consequently, prolonged use of this drug is against-indicated from 2 e  quarter. Its use, on an ad hoc basis, should only be considered if necessary.

1. In case of breastfeeding, it is preferable not to use this drug due to the absence of kinetic data on the passage of terpene derivatives in milk and the potential neurological toxicity on the infant.Iodine passes into breast milk at concentrations higher than maternal plasma.
2. Because of the risk of hypothyroidism in infants, breastfeeding is contraindicated in case of prolonged treatment with this drug.

• Solution for mouthwash:   125 ml bottle. Solution for mouthwash and gargle:  10 ml single dose containers, box of 10.

• Excipients (common): 85% glycerol, mint flavor (mint essential oil, alcohol), sodium saccharin, sodium hydroxide, purified water.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.
• from Drug Online https://bit.ly/3gtuMNa via Edrug Online

• High density polyethylene (HDPE) bottle (s) of 20 tablet (s)
• High density polyethylene (HDPE) bottle (s) of 30 tablet (s)
• High density polyethylene (HDPE) bottle (s) of 50 tablet (s)
• High density polyethylene (HDPE) bottle (s) of 100 tablet (s)
• nylon aluminum uPVC blister pack (s) of 20 tablet (s)
• nylon aluminum uPVC blister pack (s) of 30 tablet (s)
• nylon aluminum uPVC blister pack (s) of 50 tablet (s)
• nylon aluminum uPVC blister pack (s) of 100 tablet (s)

• The dosage should be adjusted according to the intensity of the pain.
• In adults: 1 to 2 tablets per dose, on average 3 times per day.
• In subjects over 65 years of age and in particular over 80 years: the dosage should be reduced by half.
• For older children aged 7 to 15: 1 to 2 tablets per 24 hours, depending on weight, under careful medical supervision.
• STRICTLY COMPLY WITH THE MEDICAL PRESCRIPTION.

• known allergy to buprenorphine or to any of the ingredients of this medication,
• children under 7,
• severe respiratory failure,
• severe liver disease,
• acute alcohol poisoning and alcohol withdrawal syndrome (delirium tremens),
• treatment with other morphine analgesics.

• Sublingual route.
• The tablets should not be swallowed or chewed: place them under the tongue and allow them to dissolve slowly.

• STRICTLY COMPLY WITH THE MEDICAL PRESCRIPTION.

• STRICTLY COMPLY WITH THE MEDICAL PRESCRIPTION.

• After sublingual administration of 0.4 mg of buprenorphine, the drug is dosed in plasma from the 30 th minute and the peak plasma concentration is reached within 2 to 3 hours.
• The absolute bioavailability is of the order of 75%.
• The biotransformation of buprenorphine takes place in the liver where it undergoes N-dealkylation and glucuronoconjugation.
• Excretion of buprenorphine occurs primarily in the bile and stool.

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton and blister, EXP. The expiration date refers to the last day of that month.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Common side effects (1% -10%): constipation, nausea, vomiting, insomnia, headache, malaise and dizziness, fatigue, drowsiness, drop in blood pressure when changing from lying or sitting to lying down or sitting down standing, sweating.
• Rare side effects (0.01% -0.1%): respiratory failure, hallucinations, hepatitis (liver damage) with jaundice.
• Other reported side effects: hypersensitivity reactions (allergy), such as rash, pruritus (itching), bronchospasm (bronchial spasm), angioedema (swelling of the face and neck which may cause breathing difficulties) and anaphylactic shock ( severe generalized allergic reaction).

• Decrease in the analgesic effect by competitive blocking of receptors, with the risk of the appearance of a withdrawal syndrome.

• Decrease in the analgesic effect by blocking the receptors with the risk of the appearance of a withdrawal syndrome.

• Alcohol enhancement of the sedative effect of buprenorphine; impaired alertness can make driving and using machines dangerous.
• Avoid taking alcoholic drinks and drugs containing alcohol.

• Increased risk of respiratory depression, which may be fatal in case of overdose.

• Increase in buprenorphine concentrations due to a decrease in its hepatic metabolism, with the risk of an increase in its adverse effects. Clinical monitoring and dosage adjustment of buprenorphine during treatment with the protease inhibitor and, if necessary, after its discontinuation.

• This medicine can cause psychological and physical dependence during prolonged treatment.
• This drug can cause drowsiness which may be increased by products such as alcoholic drinks, tranquilizers, sedative drugs, sleeping pills.
• This medicine contains lactose. Its use is not recommended in patients with lactose intolerance (a rare hereditary disease).

• In case of surgery, tell the anesthesiologist to take this medication.
• IN CASE OF DOUBT, DO NOT HESITATE TO ASK FOR THE ADVICE OF YOUR DOCTOR OR YOUR PHARMACIST.

• Clinically, there is currently no sufficiently relevant data to assess a possible malformative or fetotoxic effect of buprenorphine when it is administered during pregnancy.
• However, given the expected benefit to the mother, buprenorphine may be prescribed during pregnancy.
• During the last three months of pregnancy, chronic use of buprenorphine by the mother, regardless of the dose, can cause withdrawal syndrome in the newborn.
• In addition, at the end of pregnancy, high doses of buprenorphine, even in brief treatment, are liable to cause respiratory depression in the newborn.
• Consequently, at the end of pregnancy in the event of occasional high doses or chronic administration of buprenorphine, neonatal monitoring should be considered because of a theoretical risk of respiratory depression or withdrawal syndrome in the newborn. .

• Due to the passage of buprenorphine and its metabolites in breast milk and insufficient clinical data, it is preferable as a precaution to avoid breast-feeding in case of maternal treatment.

• Despite a large safety margin, overdose can occur with high dosages.
• In the event of accidental overdose, comprehensive management should be instituted, including close monitoring of the patient’s respiratory and cardiac status. The main symptom to be treated is respiratory depression, which can lead to respiratory arrest and death. If the patient vomits, precautions should be taken to avoid bronchial inhalation of digestive contents.

• Symptomatic treatment of respiratory depression by appropriate means should be initiated. Freedom of the upper airways should be ensured as well as controlled ventilation, or assisted if necessary. The use of an opioid antagonist (naloxone) is recommended, despite its modest effect on the respiratory symptoms due to buprenorphine, the latter being strongly bound to the morphine receptors. Doxapram can also be used.
• Postoperatively, one of the components of respiratory depression may be the residual effect of previously administered narcotics, so naloxone should be given as a first-line treatment, then the use of doxapram may be considered.
• In the event of administration of an opioid antagonist (naloxone), the long duration of action of the product should be taken into account.

• Ask the prescribing doctor for his opinion.

• Abrupt discontinuation of treatment may lead to the appearance of a withdrawal syndrome.
• If you have further questions on the use of this medicine, ask your doctor or pharmacist for more information.

• White tablet.
• 20 tablets in blister packs (Nylon / Aluminum / uPVC).

• TEMGESIC 0.3 mg / ml, solution for injection, box of 2 ampoules of 1 ml
• TEMGESIC 0.3 mg / ml, solution for injection, box of 10 ampoules of 1 ml
• TEMGESIC 0.2 mg, sublingual tablet, box of 50

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• In case of calcium deficiency following an increase in needs (growth, pregnancy, breastfeeding).
• As an adjunct to bone decalcifications in the elderly, or after menopause, corticosteroid therapy, prolonged immobilization after resumption of mobility.

• 10 sachet (s) of 4.2 g polyethylene aluminum foil
• 20 sachet (s) of 4.2 g polyethylene aluminum foil
• 30 sachet (s) of 4.2 g polyethylene aluminum foil

• history of allergy to one of the constituents,
• hypercalcaemia (abnormally high level of calcium in the blood),
• hypercalciuria (exaggerated elimination of calcium in the urine),
• Calcium lithiasis (kidney stones) – tissue calcifications,
• prolonged immobilization accompanied by hypercalcemia and / or hypercalciuria: calcium should only be administered when mobility is restored,
• due to the presence of aspartame, this drug is contraindicated in cases of phenylketonuria (hereditary disease due to an enzymatic deficiency)

• Oral route.
• After opening the sachet, put the powder in a glass, add water and drink as soon as it dissolves.

• Calcium ions are of decisive importance in the activation of biological systems. The threshold for stimulation of excitable membranes depends on the extracellular concentration of calcium ions.  
• Calcium ions further help regulate the permeability of cell membranes . 
• A deficiency of calcium ions in the plasma rises the excitability of neuromuscular , while a surplus of decreases .
• Oral administration of calcium promotes bone remineralization in cases of calcium deficiency.

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton after {EXP}. The expiration date refers to the last day of that month.
• Store away from humidity.
• Close carefully after each use.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Digestive disorders such as constipation, gas, nausea.
• In case of prolonged treatment at high doses: risk of modification of the calcium level in the blood or urine.
• extensive rash, hives and itching.

• Thiazide diuretics decrease urinary calcium excretion. Due to an increased risk of hypercalcaemia, serum calcium should be monitored regularly during concomitant treatment with thiazide diuretics.
• Systemic corticosteroids reduce the absorption of calcium. In case of concomitant use, it may be necessary to increase the dose of CALCIUM SANDOZ.
• The digestive absorption of medicinal products containing tetracycline may be reduced in the event of concomitant administration of medicinal products containing calcium. Therefore, specialties containing tetracycline should be administered at least two hours before or four to six hours after oral intake of calcium.
• The toxicity of cardiac glycosides may be increased by hypercalcemia resulting from calcium therapy. The patients must then be the subject of a clinical follow-up with control of the electrocardiogram (ECG) and the calcium level.
• Due to a decrease in the gastrointestinal absorption of bisphosphonates or sodium fluoride, it is recommended, during concomitant treatments, to observe a delay of at least three hours before taking calcium.
• Oxalic acid (found in spinach and rhubarb) and phytic acid (found in all cereals) can inhibit calcium absorption by forming insoluble complexes with calcium ions. After taking food with a high content of oxalic acid or phytic acid, the patient must wait two hours before taking products containing calcium.

• Interaction studies have only been performed in adults.
• Not applicable.

• Excessive calcium intake can be dangerous. DO NOT USE THIS MEDICINE WITHOUT MEDICAL ADVICE.

• Use this medication WITH CAUTION in case of prolonged treatment or renal failure: it is necessary to check the calcium level in the urine and in the blood.
• This medication is likely to interact with certain foods rich in oxalic acid (spinach, rhubarb, sorrel, cocoa, tea, etc.) and phytic acid (whole grains, pulses, oil seeds, chocolate, etc.), which is why it is recommended to take it away from meals containing this type of food.
• It is advisable to wait at least two hours between taking a drug based on bisphosphonates, cyclines or estramustine and taking CALCIUM SANDOZ 500 mg, powder for oral solution in sachet-dose.
• IN CASE OF DOUBT, DO NOT HESITATE TO ASK FOR THE ADVICE OF YOUR DOCTOR OR YOUR PHARMACIST.

• For pregnant and breastfeeding women, the recommended daily intake of calcium (food intake and supplement) is 1,000 to 1,300 mg.
• During pregnancy, the daily dose of calcium should not exceed 1500 mg.

• Significant amounts of calcium are secreted in milk during breastfeeding, but it does not cause any side effects in the infant.
• In case of calcium deficiency, CALCIUM SANDOZ can be administered during pregnancy and lactation.

• Nausea, vomiting, thirst intense constipation.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Powder for oral solution in sachet-dose.
• 4.2 g in sachet (Aluminum-Polyethylene paper). Box of 30 sachets.

• CALCIUM SANDOZ 500 mg, effervescent tablet, box of 1 tube of 20.

• Calcium gluconolactate 3,405 g *
• Calcium carbonate 0.15 g *

• Calcium gluconolactate.
• Calcium carbonate

• Aspartame

• Citric acid anhydrous

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• acute pneumonia,
• secondary infections of acute bronchitis, exacerbation of chronic bronchitis
• ENT infections (otitis, sinusitis, angina) and stomatological
• Urinary infections
• male genital infections and gynecological infections,
• digestive infections and bile,
• Lyme disease: treatment of the primary phase (chronic erythema migrans) and the primary phase (chronic erythema migrans associated with general signs: asthenia, headache, fever, arthralgia, etc.).
• as a relay treatment for the injectable route of endocarditis, septicemia.
• as a prophylactic treatment for bacterial endocarditis.

• in combination with another antibiotic (clarithromycin or imidazole) and an antisecretory, eradication of Helicobacter pylori in cases of peptic ulcer disease in adults (after endoscopic evidence of the lesion and infection).
• Consideration should be given to official recommendations regarding the appropriate use of antibacterials.

• One measuring spoon (5 ml) contains 125 mg of amoxicillin.
• For adults and in certain cases in children (large doses, older children), other presentations of amoxicillin are more suitable.

• The usual dosage of amoxicillin is 1-1.5 or 2 g / day in 2 to 3 doses.

• angina : 500 mg every 12 hours, for 10 days.
• In acute strep throat, a 6-day treatment at a dose of 2 g / day in 2 doses ensures eradication of the streptococcus.
• acute pneumonia: 3 g / day, or 1 g every 8 hours.
• Lyme disease :
• chronic migrant strictly isolated erythema: 4 g / 24 hours
• in the event of systemic manifestations suggesting a hematogenous dissemination of Borrelia burgdorferi , the doses may be increased up to 6 g / 24 h.
• The duration of treatment will be 15 to 21 days.
• endocarditis and septicemia (relay of the injectable route) : the dosage can be increased up to 6 g per 24 hours in at least three doses.
• prophylaxis of bacterial endocarditis :
• oral protocol: 3 g as a single dose, administered within one hour of the risky procedure,
• relay of the parenteral protocol: 1 g per os 6 hours after parenteral administration.

• amoxicillin 1 g morning and evening, combined with clarithromycin 500 mg morning and evening and omeprazole 20 mg morning and evening for 7 days, then 20 mg omeprazole daily for 3 additional weeks in case of active duodenal ulcer or 3 to 5 weeks additional in case of progressive gastric ulcer,

• amoxicillin 1 g morning and evening, combined with clarithromycin 500 mg morning and evening and lansoprazole 30 mg morning and evening, for 7 days, then 30 mg of lansoprazole per day for 3 additional weeks in case of active duodenal ulcer or 3 to 5 weeks additional in case of progressive gastric ulcer.
• The effectiveness of the treatment depends on compliance with the dosage regimen, in particular on taking the triple therapy during the first 7 days.

• The usual dose is as follows:
• for children under 30 months : 50 mg / kg / day to 100 mg / kg / day in 3 doses at 8 hours
• or children over 30 months: 25 to 50 mg / kg / day in 2 or better 3 doses without exceeding the dosage of 3 g / day.
•  For more severe infections, as well as for endocarditis and septicemia (relaying the injection route): the dosage can be increased up to 150 mg / kg / day in 3 or 4 doses, without exceeding the dosage of 6 g /day.

• Lyme Disease :
• Chronic erythema migrant strictly isolated: 50 mg / kg / 24 h
• in the event of systemic manifestations suggesting a hematogenous dissemination of Borrelia burgdorferi , the doses may be increased up to 6 g / 24 h.
• The duration of treatment will be 15 to 21 days.
• prophylaxis of bacterial endocarditis:
• Oral protocol: 75 mg / kg single dose, administered in the hour before the gesture at risk
• relay of the parenteral protocol: 25 mg / kg per os 6 hours after parenteral administration.
• angina : in acute strep throat in the over 30 month old child, a 6-day treatment at a dose of 50 mg / kg / day in 2 divided doses ensures the eradication of streptococci.

• greater than 30 ml / min: no adaptation: continue treatment with the usual dose and the recommended frequency.
• from 10 to 30 ml / min: Do / 2, every 12 hours.
• less than 10 ml / min: Do / 2, every 24 hours.
• Hemodialysis: Do, then Do / 2 per day. On dialysis days, administer Do / 2 after the dialysis session.

• This medicine can be taken with or between meals.
•  Use the measuring spoon supplied with the bottle.

• Penicillin allergy
• Cephalosporin allergy
• Child under 6
• Congenital galactosemia
• Glucose malabsorption syndrome
• Galactose malabsorption syndrome
• Lactase deficiency

• This medication MUST NEVER BE USED in case of allergy to antibiotics of the beta-lactam family (penicillins and cephalosporins) or to one of the other constituents.
• The capsule intake is contraindicated in children under 6 years of age, because it can lead to a wrong route.
• Due to the presence of lactose, this drug is contraindicated in cases of congenital galactosemia, glucose and galactose malabsorption syndrome or lactase deficiency.

• This medication SHOULD NOT GENERALLY BE USED in combination with methotrexate (see interactions).

• taken orally, amoxicillin is approximately 80 percent absorbed.
• This absorption is not influenced by food.

• The serum peak, 2 hours after the intake, reaches a level of 7 to 10 µg / ml for an intake of 500 mg and of 13 to 15 µg / mI for an intake of 1 g.
• Serum levels increase with dose.
• In subjects with normal renal functions, the half-life is 1 hour on average.
• Diffusion in most tissues and biological environments: presence of antibiotics at therapeutic rates observed in bronchial secretions, sinuses, amniotic fluid, saliva, aqueous humor, CSF, serous membranes, middle ear.
• Amoxicillin has a good diffusion in the tonsils, depending on the serum concentrations: between 1.5 and 3 hours after taking 1 gram of amoxicillin in adults, the tonsil concentrations are on average 3 to 4 µg / g .
• Amoxicillin crosses the placental barrier and passes into breast milk.
•  Protein binding rate: 17%.

• Amoxicillin is partly transformed in the body into the corresponding penicilloic acid. About 20 percent of the dose given in this form is found in the urine.

• mostly in the urine (in about 6 hours, 70 to 80 percent of the absorbed dose),
•  in the bile (5 to 10 percent).

• very common:> = 1/10.
• common:> = 1/100; <1/10.
• uncommon:> = 1/1000; <1/100.
• rare:> = 1/10000; <1/1000.
• very rare: <1/10000.

• Very rare: reversible leukopenia, neutropenia, agranulocytosis, thrombocytopenia and hemolytic anemia.
• Not known: eosinophilia.

• Very rare: convulsions.
• Not known: dizziness, headache.

• Common: diarrhea, nausea.
• Uncommon: vomiting.
• Very rare: pseudomembranous colitis, hemorrhagic colitis.
• Not known: superficial tooth staining in children, usually reversible after brushing teeth.

• Not known: acute interstitial nephritis and crystalluria.

• Common: rash.
• Uncommon: urticaria and pruritus.
• Very rare: erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome, bullous or exfoliative dermatitis. These skin manifestations may be more frequent and / or more intense in patients with infectious mononucleosis or active lymphoid leukemia. Acute generalized exanthematous pustulosis (see warnings and precautions for use).

• Frequent: mucocutaneous candidiasis.

• Very rare: anaphylaxis (including anaphylactic shock), serum sickness and hypersensitivity vasculitis (see warnings and precautions for use).
•  Not known: allergic manifestations, including urticaria, angioedema, respiratory discomfort.

• Very rare: hepatitis, cholestatic jaundice.
• Frequency not known: moderate and transient increase in serum transaminases (ALT and / or ASAT).

• Increase in the effects and hematological toxicity of methotrexate by inhibition of renal tubular secretion by penicillins.

• Increased risk of skin reactions.

• Many cases of increased activity of oral anticoagulants have been reported in patients receiving antibiotics. The marked infectious or inflammatory context, the age and general condition of the patient appear to be risk factors. Under these circumstances, it appears difficult to distinguish between the infectious pathology and its treatment in the occurrence of the INR imbalance. However, certain classes of antibiotics are more involved: these include fluoroquinolones, macrolides, cyclins, cotrimoxazole and certain cephalosporins.
• Not applicable.

• The occurrence of any allergic manifestation requires the discontinuation of treatment, and the establishment of an appropriate treatment.
• Severe and sometimes fatal hypersensitivity reactions (anaphylaxis) have been observed exceptionally in patients treated with beta-lactams.
• Their administration therefore requires an examination.
• Given a history of typical allergy to these products, the contraindication is definite.
• The penicillin allergy is crossed with the cephalosporin allergy in 5 to 10% of cases. This leads to the proscription of penicillins when the subject is known to be allergic to cephalosporins.
•  In the event of renal insufficiency, adjust the dosage according to the creatinine clearance or the creatinine level (see dosage and method of administration).
• In the event of administration of high doses of amoxicillin, sufficient fluid intake should be ensured to reduce the risk of crystalluria.
• A positive direct Coombs test was obtained during treatment with beta-lactams. This could also occur in subjects treated with amoxicillin.

• reduce assay results in blood glucose
• interfere in the determinations of the total protein level of the serum by color reaction,
• give a false positive color reaction in glycosuria assays by the semi-quantitative colorimetric method.
• Treatment of Lyme disease: Jarisch-Herxheimer reactions may occur.
• This medicinal product contains 5.7 mg of sodium per measuring spoon: take this into account only in children on a strict sodium diet.
• Due to the presence of sucrose , this medication is contraindicated in cases of fructose intolerance, glucose and galactose malabsorption syndrome or sucrase-isomaltase deficiency.
• This medicine contains 2.2 g of sucrose per measuring spoon: take this into account in the daily ration.
• Breast-feeding: there is little passage into breast milk and the quantities ingested are much lower than the therapeutic doses. As a result, breast-feeding is possible while taking this antibiotic. However, discontinue breast-feeding (or medication) if diarrhea, candidiasis, or rash occurs in the infant.

• Studies in animals have not produced any evidence of teratogenic effects. In the absence of a teratogenic effect in animals, a malformative effect in humans is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during well-conducted studies on two species.
• Clinically, analysis of a high number of exposed pregnancies apparently revealed no specific malformative or foetotoxic effects of amoxicillin. However, only epidemiological studies would make it possible to verify the absence of risk.
• Therefore, amoxicillin can be prescribed during pregnancy if needed.
• The passage of amoxicillin in breast milk is low and the amounts ingested are much lower than the therapeutic doses. As a result, breast-feeding is possible while taking this antibiotic.
• However, stop breast-feeding (or the medication) if diarrhea, candidiasis or rash occurs in the infant.

•  The manifestations of overdose can be neuropsychic, renal (crystalluria – see warnings and precautions for use) and gastrointestinal.
• Treatment is symptomatic, particularly monitoring the fluid and electrolyte balance.
• Amoxicillin can be removed by hemodialysis.

• White and orange capsule.
• 12 capsules in blister packs (PVC / Aluminum).

• HICONCIL 125 mg / 5 ml, powder for oral suspension, 60 ml vial of reconstituted suspension
• HICONCIL 250 mg / 5 ml, powder for oral suspension, 60 ml vial of reconstituted suspension
• HICONCIL 500 mg / 5 ml, powder for oral suspension, 60 ml vial of reconstituted suspension

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• 1 glass bottle (s)
• 10 glass bottle (s)

• In adults and children weighing 10 kg and over, the recommended dosage corresponds to the vitamin intake from one reconstituted vial per 24 hours.
• In children weighing less than 10 kg, the recommended dosage corresponds to the vitamin intake of one milliliter from a reconstituted vial per kilogram of weight and per 24 hours.

• in the event of known hypersensitivity to any of the components, in particular do not inject into subjects who have shown signs of intolerance to thiamine (vitamin B1) and to methyl parahydroxybenzoate;
• in combination with drugs based on levodopa.

• Strict intravenous use.
• SOLUVIT, lyophilisate for parenteral use must be reconstituted before use.
• Reconstitution is accomplished by the addition, under aseptic conditions, of an injectable lipid solution or emulsion for intravenous infusion.
• The reconstituted lyophilisate should never be injected directly into the vein, but should always be added to a solution or an emulsion for intravenous infusion, the compatibility of which with the reconstituted lyophilisate SOLUVIT has been determined beforehand.

• Vitamin B1 (thiamine): in association with ATP, formation of a coenzyme involved in the metabolism of carbohydrates.
• Vitamin B2 (riboflavin): coenzyme action in cellular energy metabolism, tissue respiration systems and macro-nutrient metabolism.
• Vitamin B3 (PP): component of NAD and NADP coenzymes involved in oxidation-reduction reactions essential for the metabolism of macro-nutrients and tissue respiration.
• Vitamin B5 (pantothenic acid): precursor of coenzyme A involved in the oxidative metabolism of carbohydrates, gluconeogenesis and synthesis of fatty acids, sterols, steroid hormones and porphyrins.
• Vitamin B6 (pyridoxine): coenzyme in the metabolism of proteins, carbohydrates and fats.
• Vitamin B12: exogenous source necessary for the synthesis of nucleoproteins and myelin, cell reproduction, growth and maintenance of normal erythropoiesis.
• Vitamin C: antioxidant properties, essential for the formation and maintenance of intercellular substance and collagen biosynthesis of catecholamines, the synthesis of carnitine and steroids, metabolism of folic acid and tyrosine.
• Folic acid: exogenous source necessary for the synthesis of nucleoproteins and the maintenance of normal erythropoiesis.
• Biotin: linked to at least four enzymes, is involved in energy metabolism including gluconeogenesis.

• Keep this medication out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the vial after EXP. The expiration date refers to the last day of that month.
• Store at a temperature not exceeding + 25 ° C and store the vial in the outer carton, in order to protect from light.
• Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

• Taking into account the presence of vitamin B1 (thiamine), it is possible to observe anaphylactic reactions in subjects presenting an allergic ground.
• If you notice any side effects not listed in this leaflet, or if any side effects get serious, please tell your doctor or pharmacist.
• Keep out of the reach and sight of children.

• Increased risk of iron-induced heart failure due to increased iron mobilization by supraphysiological vitamin C supplementation.
• In case of hemochromatosis, give vitamin C only after starting treatment with deferoxamine. Monitor cardiac function in combination. For specific precautions, refer to the Summary of Product Characteristics for deferoxamine.

• Decrease in plasma concentrations of enzyme-inducing anticonvulsants by increasing their hepatic metabolism, folate of which is one of the cofactors in the enzymatic reactions concerned, which increases the risk of convulsions.
• Clinical monitoring, monitoring of plasma levels of phenobarbital, phenytoin, primidone or fosphenytoin. Adjustment, if necessary, of the antiepileptic dosage during folic supplementation and after its discontinuation.

• May cause pyridoxine deficiency.

• Increased cytotoxicity of fluoropyrimidines when combined with folic acid.

• Blocking the conversion of folate to their active metabolites and reducing the effectiveness of supplementation.

• Some drugs can interact with certain vitamins and / or minerals at doses significantly higher than those provided by SOLUVIT, lyophilisate for parenteral use. This should be taken into account in patients receiving vitamins and / or minerals from more than one source; where appropriate, patients should be monitored for these interactions and managed appropriately.

• Depending on the reagents used, the presence of ascorbic acid in blood and urine may interfere with the results of some blood and urine glucose monitoring systems, including test strips and portable glucose monitors . precautions for use).
• This medicinal product must not be mixed with other medicinal products except those mentioned in the section Posology and method of administration.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• SOLUVIT, lyophilisate for parenteral use, does not contain any fat-soluble vitamin which is nevertheless essential in the event of exclusive parenteral nutrition.
• SOLUVIT, containing folic acid, may delay the diagnosis of Biermer’s anemia.
• SOLUVIT, lyophilisate for parenteral use must be reconstituted before use.
• The reconstituted product must not be injected directly into the vein but always added to a solution or an emulsion for infusion compatible with SOLUVIT: see.
• Check before use that the bottle is free from cracks or splinters.
• Do not keep a partially used vial.

• Studies in animals have not shown any teratogenic effect of the vitamins that make up SOLUVIT. In the absence of a teratogenic effect in animals, a malformative effect in humans is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during well-conducted studies on two species.
• In humans, there are no relevant clinical data from the use of SOLUVIT during pregnancy.
• Therefore, SOLUVIT should only be administered to pregnant women if clearly needed.

• The administration of SOLUVIT is not recommended in case of breast-feeding because of a risk of vitamin overdose in the newborn.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Lyophilisate for parenteral use:   Bottles, box of 10.

• Excipients: glycocoll, sodium edetate. Preservative: methyl parahydroxybenzoate (E218).
• Excipient with known effect: methyl parahydroxybenzoate (E218).

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Drug withdrawn from the market on 06/22/2005

•  contact eczema,
• atopic dermatitis,
• lichenification.

• stasis dermatitis,
• psoriasis (excluding very extensive plaques),
• lichen,
• genital sclero-atrophic lichen,
•  non-parasitic prurigo,
•  dyshidrosis ,
• annular granuloma,
• discoid lupus erythematosus,
• seborrheic dermatitis except for the face,
• symptomatic treatment of pruritus from mycosis fungoides.

• insect bites and parasitic prurigo after etiological treatment.
• The cream form is more particularly intended for acute, oozing lesions.

• Treatment should be limited to 1 or 2 applications per day. An increase in the number of daily applications may worsen the side effects without improving the therapeutic effects.
• The treatment of large surfaces requires monitoring the number of tubes used.
• It is advisable to apply the product in spaced strokes, then to spread it by massaging lightly until it is fully absorbed.
• Certain dermatoses (psoriasis, atopic dermatitis, etc.) make gradual cessation desirable. It can be obtained by reducing the frequency of applications and / or by using a less strong or less dosed corticosteroid.

• Hypersensitivity to any of the products contained in the preparation.
• Primary bacterial, viral, fungal or parasitic infections.
• Ulcerated lesions.
• Acne.
• Rosacea.
• Application to the eyelids (risk of glaucoma).
• Do not apply to the breasts during breastfeeding because of the risk of ingestion of the product by the newborn.

• The extent of transdermal passage and systemic effects depend on the size of the surface treated, the degree of epidermal damage, and the duration of treatment.
• These effects are all the more to be feared as the treatment is prolonged.

• The prolonged use of corticosteroids of strong activity can cause atrophy of the skin, telangiectasias (to be feared particularly on the face), stretch marks (at the root of the limbs in particular, and occurring more readily in adolescents), secondary ecchymotic purpura with atrophy, skin fragility.
• In the face, corticosteroids can create perioral dermatitis or worsen rosacea (see warnings and contraindications).
• A delayed healing of sluggish wounds, bedsores, leg ulcers can be observed (see contraindications).
• Possible systemic effects (see warnings: cushingoid syndrome, growth retardation, acute adrenal insufficiency).
• Acneiform or pustular eruptions, hypertrichosis, depigmentation have been reported.
• Secondary infections, particularly under occlusive dressing or in folds and allergic contact dermatoses have also been reported with the use of topical corticosteroids.

• Risk of hypersensitivity.
• Yellow discoloration of the skin, disappearing quickly.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Prolonged use on the face of moderately active corticosteroids exposes the occurrence of corticosteroid-induced and paradoxically corticosensitive dermatitis, with rebound after each stop. A gradual weaning, particularly difficult, is then necessary.
• Due to the passage of the corticosteroid into the systemic circulation, treatment over large areas or under occlusion may cause the systemic effects of systemic corticosteroid therapy, particularly in infants and toddlers.
• They consist of a cushingoid syndrome and a slowing of growth. These accidents disappear when treatment is stopped, but abrupt cessation can be followed by acute adrenal insufficiency.

• In infants, it is preferable to avoid corticosteroids of strong activity. It is necessary to be particularly wary of the phenomena of spontaneous occlusions which can occur in the folds and under the layers.
• In the event of a bacterial or mycotic infection of a corticosensitive dermatosis, precede the use of the corticosteroid with a specific treatment.
• If an intolerance appears, the treatment must be interrupted and the cause must be sought.

• Animal teratogenesis studies have not been performed with topical corticosteroids. However, studies of oral corticosteroids in pregnant women have not shown a higher risk of malformation than that observed in the general population.
• Accordingly, these drugs can be prescribed during pregnancy if needed.

• Breast-feeding is possible while taking this medicine.
• Do not apply to the breasts during breastfeeding because of the risk of ingestion of the product by the newborn.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Not applicable.
• Not applicable.
• Not applicable.
• Not applicable.

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

• Chlorhexidine is a disinfectant. It inhibits the growth of bacteria and fungi.
• For wounds, such as abrasions or cuts, if they are infected or if there is a risk of infection. Also to disinfect objects or to disinfect the skin before a minor procedure. And to prevent boils from recurring.
• Cream or lotion: first clean the wound with lukewarm water. Pat the skin dry. First let an abrasion dry in the air. Apply chlorhexidine. Some lotions are flammable. Therefore, stay away from an open flame such as a cigarette.
• Do you have a skin infection? Prevent the infection from spreading to other parts of the body or from infecting other people. Therefore, do not scratch the spots. If necessary, cover the affected skin with a plaster or bandage. Also use your own towel.
• You may experience mild skin irritation. Especially if you use it for more than a few weeks or on sensitive body parts. This will disappear by itself. Do you continue to suffer? Then consult your doctor.
• Do not get chlorhexidine in the eyes, mouth, or nose. This causes irritation.

• In case of a skin infection, bacteria penetrate the skin and cause inflammation. It can arise from damage to the skin, such as eczema, bedsores, cuts and razor wounds.
• You may notice a skin infection by redness, pain or itching, swelling or pus.

• Chlorhexidine fights different types of bacteria and some types of fungi. It destroys the cell wall of these bacteria and fungi, causing them to die.

• With slightly infected scrapes or cuts, you can use chlorhexidine to disinfect the skin. The body then cleans up the bacteria itself.
• You can also use chlorhexidine to prevent infection. For example on the skin before a minor procedure or examination or on the skin and mucous membranes of the vagina after birth.
• The chlorhexidine solution is also applied to certain objects that need to be disinfected. Consult the instructions on the packaging or your pharmacy for this.

• With a superficial scrape or cut, it is important that the wound does not become infected. Therefore, disinfect the wound with, for example, chlorhexidine.
• Then cover the wound with gauze or bandage. First let an abrasion dry in the air.

• Chlorhexidine fights different types of bacteria and some types of fungi. It destroys the cell wall of these bacteria and fungi, causing them to die.

• A boil can develop when a hair follicle becomes inflamed with a bacteria. The pus in the hair follicle accumulates and causes a painful pimple.
• After a few days to two weeks, the pimple breaks through, allowing the pus to drain.

• Always see your doctor with a boil on the face.
• Disinfect a (broken) boil and the skin around it with chlorhexidine. This prevents the bacteria from spreading and creating new boils.
• Do you often have a boil or does it keep coming back? You can try to avoid this by washing the skin 2 to 3 times a week with soap containing chlorhexidine.

• chlorhexidine is Active ingredients in ChloraPrep

• First, clean the skin by rinsing with lukewarm water. Optionally, you can use a disinfectant soap or a pH-neutral wax emulsion. Avoid using regular soap as it can irritate the skin and make the condition worse.
• Then pat the skin dry.
• You can remove crusts by soaking them in baby oil or with a solution of 1 teaspoon of table salt in 1 glass of water, which you always prepare fresh.
• Then apply the cream, lotion or solution:
• Cream : apply the cream thinly. If necessary, you can cover the rubbed area with a sterile bandage or plaster.
• Lotion, solution : apply the solution with gauze to the wound and the skin around it. If necessary, you can cover the rubbed area with a sterile bandage or plaster. Some lotions are flammable. Therefore, stay away from an open flame such as a cigarette.
• Avoid contact with the eyes and do not let the medicine get into the mouth or nose as this can cause irritation. If it does get into the eyes, rinse immediately with water.
• Note: This medicine can stain clothes or linens. These are difficult to wash out.
• In case of a skin infection, try to prevent others from becoming infected and the condition from spreading further into the body by taking the following measures.
• Do not scratch the spots. Cut the nails short and tape off the affected skin if necessary. Always clean under the nails.
• Use your own towel.

• Apply the soap solution to damp skin. Rub in for several minutes. Foam will form. Rinse and dry with sterile gauze if necessary.
• Avoid contact with the eyes and do not let the medicine get into the mouth or nose as this can cause irritation. If it does get into the eyes, rinse immediately with water.
• Note: This medicine can stain clothes or linens. These are difficult to wash out.

• Divide the treatments as well as possible over the day. Then the drug has a constant effect. How long it works depends on the strength of the preparation. The stronger preparations (0.5% chlorhexidine or more) work for about six hours. You can apply these products every six hours.

• You can apply this drug for as long as you want. Bacteria usually do not become insensitive to this drug, even if you use it for a long time.
• If the condition spreads, you should contact the doctor.

• Antiseptics of the bisbiguanide family destroy bacterial cells by non-specific interaction with acidic phospholipids in the cell membrane.
• Chlorhexidine Gluconate is a cationic biguanide. Its antimicrobial activity is related to the destruction of the cell membrane and the precipitation of the contents of the cell. It has a bactericidal or bacteriostatic effect on a large number of Gram-positive and Gram-negative bacteria. It is relatively ineffective against mycobacteria. It inhibits certain viruses and is found to be active against certain fungi. It is inactive against bacterial spores. It has a higher residual power compared to currently available skin antiseptics. Chlorhexidine gluconate has a strong binding power with the skin and a documented cutaneous residual power at 48 hours. Chlorhexidine gluconate is not neutralized in the presence of organic substances.
• Isopropyl alcohol is a fast acting, broad spectrum bactericidal antiseptic, but it is not considered to be persistent. It seems to act according to a mechanism of protein denaturation.

• CHLORAPREP, solution for skin application is a sterile antiseptic solution combining 2% chlorhexidine gluconate and 70% isopropyl alcohol, which is effective in rapidly and persistently reducing the bacterial density on various parts of the body for a large spectrum of organisms. Isopropyl alcohol (70%) ensures the immediate destruction of transient and resident microorganisms on the stratum corneum, and chlorhexidine gluconate (2%) binds to the surface layers of cells in the epidermis and exerts a residual antimicrobial effect (persistent) which prevents the multiplication of microorganisms.

• Standard EN 1040 – Basic bactericidal activity (phase 1)
• Standard EN 1275 – Basic fungicidal activity (phase 1)
• Standard EN 13727 – Bactericidal activity (phase 2 / step 1)
• Standard EN 13624 – Fungicidal activity (phase 2 / step 1)

• In very rare cases (<1 / 10,000), allergic skin reactions or skin irritation to chlorhexidine and isopropyl alcohol have been reported: erythema, rash (erythematous, papular or maculopapular), pruritus and blisters or blisters on the application site. Other local symptoms include a burning sensation, pain and inflammation of the skin.
• Frequency is unknown for: dermatitis, eczema, urticaria, chemical burns in newborns.

• The frequency is not known for: hypersensitivity including anaphylactic shock (see sections Contraindications and Warnings and precautions for use).
• The most frequently reported adverse reactions are related to application site reactions. It was noted that these reactions occurred most often in the application area (that is to say at the site to be prepared) and only very rarely spread. These reactions were often transient, or disappeared following topical treatment with corticosteroids or antihistamines. The most frequently reported reactions were mild in nature; they included rash, erythema, blisters, pain or itching localized at the application site. The frequency, nature and severity of adverse reactions in children are expected to be the same as in adults.
• Cases of anaphylactic reactions have been reported during anesthesia.

• The frequency is unknown for: eye irritation, pain, hyperemia, impaired vision, chemical burn, eye injury.

• There have been spontaneous reports of generalized allergic reactions potentially associated with ChloraPrep solutions and reported during anesthesia. In some cases, the patient may have had a pre-established sensitivity to chlorhexidine .
• This product can cause severe allergic reactions. Symptoms may include wheezing, difficulty breathing, shock, swelling of the face, hives, or rash. The use of CHLORAPREP, solution for skin application is contraindicated when patients have shown a history of hypersensitivity to chlorhexidine or isopropyl alcohol (see section Contraindications). If hypersensitivity or allergic reaction occurs, discontinue use and seek medical help immediately.

• Remove all materials, sheets and soaked gowns before continuing the procedure. Do not use excessive amounts and do not allow the solution to stagnate in folds of the skin or under the patient or drip on sheets or other materials in direct contact with the patient. When occlusive dressings are to be applied to areas previously exposed to CHLORAPREP, solution for skin application, ensure that there is no excess of product before applying the dressing.
• For external use only on healthy skin.
• CHLORAPREP, solution for skin application contains chlorhexidine. Chlorhexidine is known to induce hypersensitivity, including generalized allergic reactions and anaphylactic shock. The prevalence of hypersensitivity to chlorhexidine is not known, but the existing literature suggests that it is probably very rare. CHLORAPREP, solution for skin application should not be administered to anyone with a history of allergy to a compound containing chlorhexidine.
• The solution is irritating to the eyes and mucous membranes. It should therefore be kept away from these areas. If the solution comes into contact with the eyes, rinse immediately with plenty of water.
• Do not use on open skin wounds. Do not use on skin with lesions or cuts. In addition, direct contact with nerve tissue or the middle ear should be avoided.
• Prolonged skin contact with solutions containing alcohol should be avoided.
• It is important to ensure that the recommended method of application is strictly followed (see section Dosage and method of administration above). If the solution is applied too vigorously to very fragile or sensitive skin, or if used repeatedly, a local skin reaction may occur: erythema or inflammation, pruritus, dry and / or flaky skin and pain in the chest area. site. At the first signs of a local skin reaction, stop applying CHLORAPREP, solution for skin application.
• Anaphylactic reactions during anesthesia.
• Products containing chlorexhidine are known causes of anaphylactic reactions during anesthesia.
• Symptoms of anaphylactic reactions may be masked in the anesthetized patient. For example, a significant portion of the skin may be covered or the patient is unable to communicate early symptoms.
• If symptoms of an anaphylactic reaction are detected during anesthesia (eg sudden drop in blood pressure, hives, angioedema), an allergic reaction associated with chlorexhidine should be considered. When an allergic reaction associated with chlorhexidine during anesthesia is suspected, other products containing chlorhexidine and used during anesthesia (eg IV lines) should be removed. Special care should be taken to avoid exposure of patients to any other product containing chlorhexidine during treatment.

• The use of chlorhexidine solutions, alcoholic and aqueous, for antisepsis of the skin before invasive procedures has been associated with chemical burns in newborns. Based on available case reports and published literature, this risk appears to be higher in premature infants, especially those born before 32 weeks of pregnancy, and in the first 2 weeks of life.

• No effects during pregnancy are expected as systemic exposure to chlorhexidine gluconate is negligible. ChloraPrep can be used during pregnancy.

• No effects in breastfed newborns / infants are expected as the systemic exposure of lactating women to chlorhexidine gluconate is negligible. ChloraPrep can be used during breast-feeding.

• The effects of chlorhexidine gluconate on human reproduction have not been studied.

• 0.67 mL (Sepp): 200 applicators
• 1 mL: 60 applicators
• 1.5 mL (Frepp): 20 applicators
• 1.5 mL and 3 mL: 1 applicator or 25 applicators
• 10.5 mL: 1 applicator or 25 applicators
• 26 mL: 1 applicator

• CHLORAPREP, solution for skin application, box of 200 applicators with 0.67 mL ampoules
• CHLORAPREP, solution for skin application, box of 25 applicator with 1.50 ml ampoules

•  is not present in the composition of this drug

• Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

• General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

• For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

• It treats possible side effects and drug interactions that require attention and its effect on continuous use.
• The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.